COLO-RECTAL CANCER (DMMR/MSI-H CRC)
Clinical trials for COLO-RECTAL CANCER (DMMR/MSI-H CRC) explained in plain language.
Never miss a new study
Get alerted when new COLO-RECTAL CANCER (DMMR/MSI-H CRC) trials appear
Sign up with your email to follow new studies for COLO-RECTAL CANCER (DMMR/MSI-H CRC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in shrinking hard-to-treat colorectal tumors before surgery
Disease control Recruiting nowThis study looks at how well the drug tislelizumab works when given before surgery for people with a specific genetic type of stage II-III colorectal cancer (dMMR/MSI-H). About 30 participants will receive three cycles of the drug, then have surgery to remove the tumor. Researche…
Matched conditions: COLO-RECTAL CANCER (DMMR/MSI-H CRC)
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
Shot vs. drip: cancer patients pick their preferred way to get immunotherapy
Knowledge-focused Recruiting nowThis study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…
Matched conditions: COLO-RECTAL CANCER (DMMR/MSI-H CRC)
Phase: PHASE2 • Sponsor: Diwakar Davar • Aim: Knowledge-focused
Last updated May 07, 2026 18:39 UTC